ストックスクリーナーアプリを入手
40.53
0.57%
0.23
プレマーケット:
41.38
0.85
+2.10%
前日終値:
$40.30
開ける：
$41
24時間の取引高:
1.35M
Relative Volume:
0.79
時価総額：
$3.46B
収益：
$170.10M
当期純損益:
$-239.59M
株価収益率:
-14.48
EPS:
-2.8
ネットキャッシュフロー:
$-191.20M
1週間 パフォーマンス:
+2.12%
1か月 パフォーマンス:
-9.19%
6か月 パフォーマンス:
-32.99%
1年 パフォーマンス:
-33.40%
1日の値動き範囲:
$40.45
$41.55
1週間の範囲:
$36.52
$41.55
52週間の値動き範囲:
$36.52
$91.10
Crispr Therapeutics Ag Stock (CRSP) Company Profile
CRSP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
40.53 | 3.46B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-08-02 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-28 | 再開されました | Guggenheim | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-11 | ダウングレード | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 開始されました | Mizuho | Buy |
| 2023-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-04-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2023-03-07 | 開始されました | Robert W. Baird | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-08-09 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | アップグレード | Citigroup | Sell → Neutral |
| 2021-04-21 | アップグレード | Jefferies | Hold → Buy |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2020-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-10 | 繰り返されました | Needham | Buy |
| 2020-12-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-07-28 | 繰り返されました | Needham | Buy |
| 2020-07-14 | 開始されました | SunTrust | Buy |
| 2020-06-15 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-19 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 開始されました | Jefferies | Buy |
| 2019-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-10 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-14 | 開始されました | William Blair | Mkt Perform |
| 2019-01-28 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-22 | ダウングレード | Citigroup | Neutral → Sell |
すべてを表示
Crispr Therapeutics Ag (CRSP) 最新ニュース
CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Up 5.4% in December - MarketBeat
Gene Editing Market Overview and Leading Players: Horizon - openPR
Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia - Benzinga
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell? - MSN
CRISPR Therapeutics AG (CRSP): The Biotech Stock with Biggest Upside Potential - Insider Monkey
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year - Investing.com India
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
7,536 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Mirador Capital Partners LP - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Vertex's Pain Drug: Big Pharma's Next Major Success? - Benzinga
My 10 Top Stocks to Buy to Start the New Year Off Right - The Motley Fool
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers - Seeking Alpha
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 1-Year LowTime to Sell? - MarketBeat
Genome Engineering Market Is Booming Worldwide 2024-2031 | Thermo Fisher Scientific Inc., CRISPR Therapeutics - EIN News
CRISPR Therapeutics' (CRSP) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
How to Take Advantage of moves in (CRSP) - Stock Traders Daily
CRISPR Therapeutics outlines 2025 strategic goals By Investing.com - Investing.com Canada
CRISPR Therapeutics (NASDAQ:CRSP) Hits New 12-Month LowWhat's Next? - MarketBeat
CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10+ Major Market Players - Yahoo Finance UK
CRISPR Therapeutics stock hits 52-week low at $38.2 - Investing.com India
CRISPR Therapeutics stock hits 52-week low at $38.2 By Investing.com - Investing.com Nigeria
CRISPR Therapeutics outlines 2025 strategic goals - Investing.com India
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones - GlobeNewswire
CRISPR Therapeutics (CRSP) Highlights Strategic Priorities and Anticipated 2025 Milestones - StreetInsider.com
CRISPR Therapeutics Reveals 2025 Pipeline Plans: CASGEVY Success Drives $1.9B Cash Position - StockTitan
Catherine Wood's Recent Transaction with CRISPR Therapeutics AG - GuruFocus.com
Brookline Capital Management Estimates CRSP FY2024 Earnings - MarketBeat
Equities Analysts Issue Forecasts for CRSP FY2029 Earnings - MarketBeat
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Interesting CRSP Put And Call Options For February 28th - Nasdaq
CRISPR Therapeutics to add Briggs Morrison to Board By Investing.com - Investing.com South Africa
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note - MSN
Bank of America Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $85.00 - MarketBeat
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025 - MarketBeat
CRISPR Therapeutics to add Briggs Morrison to Board - Investing.com
Intellia Thera CS (NTLA-Q) QuotePress Release - The Globe and Mail
CRISPR Therapeutics Proposes New Appointment to the Board of Directors - GlobeNewswire
CRISPR Therapeutics Strengthens Board with Former AstraZeneca Clinical Development Leader - StockTitan
Check Out What Whales Are Doing With CRSP - Benzinga
Capital Market Strategies LLC Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
How To Trade (CRSP) - Stock Traders Daily
Top 5 CRISPR Companies To Invest In (January 2025) - Securities.io
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know - MSN
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Not Quite Adding Up - Simply Wall St
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to Sell Rating - MarketBeat
Why Is CRISPR Therapeutics AG (CRSP) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week LowWhat's Next? - MarketBeat
CRISPR Therapeutics stock hits 52-week low at $39.31 By Investing.com - Investing.com Nigeria
CRISPR Therapeutics stock hits 52-week low at $39.31 - Investing.com
Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025 (NASDAQ:CRSP) - Seeking Alpha
Crispr Therapeutics Ag (CRSP) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):